Perhaps my previous posting is not correct or accurate as I told: "it can now start to work according to the plan". ATH needs to do some preclinical studies and utilize data from a natural history study that has not been done yet. I just hope that the word "encourage" does not mean "must" to wait for this natural history study results. It could be that this plan with Vanderbilt is enough advice.
Ann: Meeting with US FDA provides development path for ATH434, page-6
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $100.4M | |||
| Open | High | Low | Value | Volume |
| 1.1¢ | 1.1¢ | 1.1¢ | $88.06K | 8.054M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 29 | 11330464 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 1574126 | 5 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| ATH (ASX) Chart |